XCancer

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Description:

The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.

Sponsor:

Unknown Organization

Phase:

Phase 2/3

Contacts:

Ebrahim Delpassand, M.D. (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT00442533 - Click here to see study on

ClinicalTrials.gov

Pentetreotide

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DTPA
Inclusion
  • Patients must be greater than 18 years of age.
  • All patients must have a Karnofsky performance status of at least 60.
  • All patients must sign an informed consent indicating the awareness of the investigational nature of the studies involved.
  • Patients must have evidence of residual multifocal active tumor.
  • * Patients must have received first line standard chemotherapy and/or radiation therapy for neuroendocrine malignancy in the past and failed the therapy.
Exclusion
  • Patients under 18 years of age. There will be no upper age discrimination.
  • Patients with renal insufficiency as defined by a calculated creatinine clearance (based on age, weight and serum creatinine) of 39.9 ml/min or less.
  • Patients who are pregnant or those potentially pregnant subjects not willing to practice effective contraceptive techniques during the study period.
  • * Karnofsky performance status of 50 or less.
  • Patients who are unable to give informed consent.